Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Venn Life CEO Richardson comments on Kinesis deal

Tony Richardson, chief executive Venn Life Sciences (LON:VENN), says the company’s acquisition of Dutch drug consultancy Kinesis allows it to pair early and late-stage drug development together.

Venn currently offers clinical trial management, monitoring and biometric data services to customers in the later phases of developing treatments.

But Kinesis will allow it to supply more early-stage technical services, such as working out how a drug should be administered or how quickly it has worked its way through the body.

 
Meet Acal Plc and Scancell Holdings Plc at our event, London, 07 July 2016. Register here »
Sarah_55b0a64c2a6b3.jpg
Why Invest In Venn Life Sciences Holdings plc? Read More Here

Register here to be notified of future Venn Life Sciences Holdings plc articles
View full VENN profile

Venn Life Sciences Holdings plc Timeline

Article
May 10 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.